TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis (Businesswire) - Oct 12, 2026 - "The analysis used individual patient-level data from 545 BRIUMVI (ublituximab)-treated participants in the Phase 3 ULTIMATE I and II trials and their open-label extension and compared outcomes with published aggregate data from the Phase 3 OPERA I/II trials of ocrelizumab and ASCLEPIOS I/II trials of ofatumumab....BRIUMVI was associated with a lower risk of 24-week confirmed disability progression (CDP24) compared with both ocrelizumab and ofatumumab, with a 44% lower relative hazard versus ocrelizumab (HR 0.560; 95% CI: 0.380–0.826) and a 49% lower relative hazard versus ofatumumab (HR 0.509; 95% CI: 0.350–0.741); BRIUMVI was associated with a lower cumulative incidence of CDP24 at 240 weeks, with estimated rates of 9.3% versus 16.1% for ocrelizumab and 9.4% versus 17.9% for ofatumumab."
Retrospective data • Immunology • Multiple Sclerosis
|